Anticancer activity of novel extracts from Cautleya gracilis (Smith) Dandy: apoptosis in human medullary thyroid carcinoma cells.

BACKGROUND Medullary thyroid carcinoma (MTC) is a calcitonin-producing tumor of the thyroid arising from the parafollicular C-cells. MTC is poorly responsive to chemotherapy and radiotherapy, hence the only effective therapy is surgery. Based on this fact, alternative strategies have been sought. MATERIALS AND METHODS The effects of Cautleya gracilis (Smith) Dandy were investigated for the first time in three human MTC cell lines and in MTC-transplanted mice. Proliferation and viability were quantified by cell counting, WST-1 tests, and ATP luminescent cell viability assays. Apoptosis was studied by DAPI staining, flow cytometry and luminescent assays for caspases 3/7, 8 and 9. RESULTS A dose-dependent reduction of proliferation and an induction of apoptosis were found in all MTC cell lines, while normal fibroblasts were not impaired. Similar tumor inhibition was seen in heterotransplanted mice. CONCLUSION Our in vitro and in vivo findings suggest a new potential clinical effect of Cautleya.

[1]  H. Stuppner,et al.  The dichloromethane fraction of Stemona tuberosa Lour inhibits tumor cell growth and induces apoptosis of human medullary thyroid carcinoma cells , 2007, Biologics : targets & therapy.

[2]  H. Katinger,et al.  Development of standardized cell culture conditions for tumor cells with potential clinical application. , 2007, Cytotherapy.

[3]  M. Gnant,et al.  Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination. , 2005, Anticancer research.

[4]  E. Ingolič,et al.  Culture of Human Neuroendocrine Tumor Cells , 2005 .

[5]  T. Efferth,et al.  Activity of novel plant extracts against medullary thyroid carcinoma cells. , 2004, Anticancer research.

[6]  P. Olive,et al.  Drug and radiation resistance in spheroids: cell contact and kinetics , 1994, Cancer and Metastasis Reviews.

[7]  I. Raskin,et al.  Plants and human health in the twenty-first century. , 2002, Trends in biotechnology.

[8]  E. Ingolič,et al.  Medullary thyroid carcinomas in cell culture--models for future therapies. , 2002, Wiener klinische Wochenschrift.

[9]  A. Abbruzzese,et al.  Current approaches and perspectives in the therapy of medullary thyroid carcinoma , 2001, Cancer.

[10]  R. Kerbel,et al.  Cell adhesion and drug resistance in cancer , 1997, Current opinion in oncology.

[11]  L. Mulligan,et al.  Mutations of the RET proto‐oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease , 1997, Human mutation.

[12]  G. Fontanini,et al.  Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. , 1997, British Journal of Cancer.

[13]  M. Santoro,et al.  Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line , 1995 .

[14]  M. Santoro,et al.  Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. , 1995, Biochemical and biophysical research communications.

[15]  E. Ingolič,et al.  New continuous cell-line from human medullary-thyroid carcinoma - sinj - phenotypic analysis and invivo carcinogenesis. , 1993, International journal of oncology.

[16]  N. Samaan,et al.  Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. , 1991, Anticancer research.

[17]  H. Höfler,et al.  Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. , 1990, Cancer research.

[18]  J. Rhim,et al.  Survival of human cells in the aggregate form: potential index of in vitro cell transformation. , 1977, Journal of the National Cancer Institute.